REGN
CompareRegeneron Pharmaceuticals Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite ®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center ® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
Did you know?
Profit margin of 31.4% — that's well above average.
Current Price
$766.02
+2.60%GoodMoat Value
$1382.84
80.5% undervaluedProfile
Valuation (TTM)
Market Cap$80.51B
P/E17.87
EV$71.51B
P/B2.58
Shares Out105.10M
P/Sales5.61
Revenue$14.34B
EV/EBITDA12.82
Regeneron Pharmaceuticals Inc (REGN) Stock Analysis
GoodMoat Analysis
Regeneron is a high-quality biotechnology company with a strong competitive moat, trading at a price that appears deeply undervalued relative to its intrinsic value. The company's profitability and financial health are excellent, though its current revenue growth is modest. For a value investor, it presents a compelling case for deeper investigation.
Read full analysis
Regeneron Pharmaceuticals is a leading biotechnology firm focused on the discovery, development, and commercialization of medicines for serious diseases. Its core competitive advantages, or moat, are anchored in Technology Leadership and Proprietary Data. The company's foundational VelocImmune platform for creating human antibodies is a significant, patented innovation that is difficult to replicate. This, combined with a deep pipeline and strategic partnerships, likely yields a Moat Score comfortably above the 5+ threshold required to proceed. Financially, the company exhibits high quality with a strong profit margin of 31.4%, a robust ROE of 14.4%, and a very conservative balance sheet with minimal debt. However, the current revenue growth of 2.5% YoY is a point for scrutiny. Applying the GoodMoat Decision Framework, the business passes the Moat & Quality Gate. Crucially, the current price of $749.47 is significantly below the platform's estimated intrinsic value target of $1,382.84, implying a margin of safety well over 40%, which the framework classifies as 'Deeply Undervalued.' This substantial discount, coupled with the company's durable advantages and financial strength, makes the investment case favourable from a value perspective, warranting a thorough review of its growth drivers and pipeline sustainability. Analysis based on data as of 2024-05-15.
Market Cap$80.51B
Current Price$766.02
P/E Ratio17.87
Forward P/E—
PEG Ratio-5.09
EPS$41.48
Book Value$297.40
P/B Ratio2.58
REGN Financial Charts
REGN 52-Week Range
$481.18
$811.29
50-Day MA: $763.70200-Day MA: $677.69
Did you know?
Price sits at 86% of its 52-week range.
Regeneron Pharmaceuticals Inc (REGN) Financial Summary
Regeneron Pharmaceuticals Inc (REGN) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. The stock currently trades at $766.02 with a market capitalization of $80.51B.
Key valuation metrics include a P/E ratio of 17.87, price-to-book ratio of 2.58, and EPS of $41.48. The company reports a profit margin of 31.4% and return on equity of 14.4%.
REGN Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $80.51B |
| P/E Ratio | 17.87 |
| EPS | $41.48 |
| P/B Ratio | 2.58 |
| P/S Ratio | 5.61 |
| EV/EBITDA | 12.82 |
| Dividend Yield | 0.46% |
| Profit Margin | 31.4% |
| Return on Equity | 14.4% |
| Debt/Equity | 0.09 |
Regeneron Pharmaceuticals Inc (REGN) Valuation
Based on GoodMoat's DCF model, Regeneron Pharmaceuticals Inc has a fair value estimate of $1382.84. At the current price of $766.02, the stock appears 44.6% undervalued relative to our intrinsic value estimate.
REGN Quality Indicators
Regeneron Pharmaceuticals Inc maintains a profit margin of 31.4% and an operating margin of 24.9%. Return on equity stands at 14.4%. The current ratio is 4.13. Debt-to-equity ratio is 0.09.
About Regeneron Pharmaceuticals Inc
Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite ®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center ® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
REGN Free Cash Flow
Regeneron Pharmaceuticals Inc generated $4.08B in trailing twelve-month free cash flow, representing an FCF yield of 5.07%. This strong FCF yield suggests the company generates substantial cash relative to its market value.
REGN Shares Outstanding
Regeneron Pharmaceuticals Inc has 0.11 billion shares outstanding at a share price of $766.02, giving it a market capitalization of $80.51B.
REGN Recent Insider Trades
Recent insider transactions at Regeneron Pharmaceuticals Inc include:
| Insider | Type | Shares | Value |
|---|---|---|---|
| RYAN ARTHUR F | SELL | 1 | $771.32 |
| RYAN ARTHUR F | SELL | 7 | $5442.22 |
| Zoghbi Huda Y | SELL | 49 | $37959.32 |